Evommune Inc. picked up rights outside of greater China to an oral, preclinical VAV1-directed molecular glue degrader (MGD) ...
Qyuns Therapeutics Co. Ltd. is expanding its partnership with Caldera Therapeutics through a potential $780 million deal for ...
This summer’s U.S. FDA clearance of the oral pan-RAS inhibitor Rasonque (daraxonrasib) from Revolution Medicines Inc. provided hope for pancreatic ductal adenocarcinoma (PDAC) patients, and results ...
Despite a concerted effort to speed trial setup, the number of patients taking part in industry-sponsored clinical studies in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results